On Jul. 20, 2021, Roche announced that Japanﾒs Ministry of Health, Labour and Welfare (MHLW) had approved Ronapreveﾙ(casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion.

The MHLW was based the approval on results from the global phase III REGN-COV 2067 study in high-risk non-hospitalised patients with COVID-19, which showed that casirivimab and imdevimab reduced hospitalisation or death by 70%.